Lee Pureum, Kim Doo-Jin
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.
University of Science and Technology (UST), Daejeon 34113, Korea.
Immune Netw. 2020 Jul 22;20(4):e28. doi: 10.4110/in.2020.20.e28. eCollection 2020 Aug.
The recent emergence of the novel coronavirus (CoV) or severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a global threat to human health and economy. As of June 26, 2020, over 9.4 million cases of infection, including 482,730 deaths, had been confirmed across 216 countries. To combat a devastating virus pandemic, numerous studies on vaccine development are urgently being accelerated. In this review article, we take a brief look at the characteristics of SARS-CoV-2 in comparison to SARS and Middle East respiratory syndrome (MERS)-CoVs and discuss recent approaches to coronavirus disease-2019 (COVID-19) vaccine development.
新型冠状病毒(CoV)即严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的近期出现,对人类健康和经济构成了全球威胁。截至2020年6月26日,216个国家已确诊超过940万例感染病例,其中包括482730例死亡病例。为抗击这场毁灭性的病毒大流行,众多关于疫苗研发的研究正在紧急加速推进。在这篇综述文章中,我们简要对比了SARS-CoV-2与SARS及中东呼吸综合征(MERS)-CoV的特征,并讨论了2019冠状病毒病(COVID-19)疫苗研发的最新方法。